HitGen(SH:688222) Xin Lang Cai Jing·2025-11-24 02:40Group 1 - Chengdu XianDao Pharmaceutical Development Co., Ltd. experienced a stock price increase of 5.12%, reaching 22.58 CNY per share, with a trading volume of 102 million CNY and a turnover rate of 1.14%, resulting in a total market capitalization of 9.047 billion CNY [1] - The company, established on February 22, 2012, and listed on April 16, 2020, specializes in early-stage drug discovery services using its core DEL technology, with 99.97% of its revenue coming from new drug development services [1] - The revenue breakdown includes customized services at 59.92%, full-time equivalent services at 27.20%, and other services at 12.84%, with a negligible 0.03% from other sources [1] Group 2 - Huatai-PB Fund has a significant holding in Chengdu XianDao, with the Zhongzheng 2000 fund (563300) holding 453,900 shares, representing 0.52% of the fund's net value, making it the eighth largest holding [2] - The Zhongzheng 2000 fund, established on September 6, 2023, has a current scale of 2.168 billion CNY and has achieved a year-to-date return of 23.2%, ranking 1657 out of 4208 in its category [2] - The fund's one-year return stands at 17.97%, ranking 1859 out of 3981, while its cumulative return since inception is 25.13% [2] Group 3 - The fund managers of Zhongzheng 2000 are Liu Jun and Li Mu Yang, with Liu Jun having a tenure of 16 years and 178 days, managing assets totaling 542.504 billion CNY, achieving a best return of 143.46% and a worst return of -45.64% during his tenure [3] - Li Mu Yang has a tenure of 4 years and 324 days, managing assets of 29.768 billion CNY, with a best return of 121.13% and a worst return of -43.11% during his tenure [3]